Serentis Ltd. Report issue

For profit Phase 2
Founded: Cambridge United Kingdom (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2009
NCT00838708
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

nalmefene (revex) (1 trial)

srd441 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Pruritus (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2